- Home
- EVAX vs CNSP Comparison
EVAX vs CNSP Comparison
Compare EVAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVAX | CNSP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.7M | 4.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EVAX | CNSP |
|---|---|---|
| Price | $4.75 | $6.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $12.33 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 105.1K | 14.3K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,650,000.00 | N/A |
| Revenue This Year | $128.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | $4.93 |
| 52 Week High | $12.15 | $114.00 |
Technical Indicators
Market Signals| Indicator | EVAX | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 42.44 |
| Support Level | $5.72 | $7.01 |
| Resistance Level | $6.70 | $7.78 |
| Average True Range (ATR) | 0.52 | 0.61 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 5.22 | 20.10 |
Price Performance
Historical ComparisonAbout EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.